OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

HTML

Year: 2012
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-11-1991
Authors: Richard S. Finn, Yoon-Koo Kang, Mary Mulcahy, Blase N. Polite, Ho Yeong Lim, Ian Walters, Christine Baudelet, Demetrios Manekas, Joong-Won Park
Institutions: Northwestern University, University of California, Los Angeles, Samsung Medical Center, University of Ulsan, University of Chicago Medical Center, Sungkyunkwan University, Bristol-Myers Squibb (United States)
Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: brivanib, advanced hepatocellular carcinoma, second-line therapy, anti-angiogenic therapy, sorafenib-refractory disease, tumor response rate, progression-free survival, overall survival, safety and tolerability
SDG: Good health and well-being

Open Access status: closed

Funders: Bristol-Myers Squibb, National Cancer Institute
Award: G3680653400
OpenAlex ID: W2145803146
FWCI: 25.27
Cites: 54
Cited by: 224
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms